[(E,2R,3S)-3-hydroxy-2-methyloctadec-4-enyl] methyl hydrogen phosphate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磷酸及其衍生物
• 英文名称: [(E,2R,3S)-3-hydroxy-2-methyloctadec-4-enyl] methyl hydrogen phosphate
• 化学式: C₂₀H₄₁O₅P
• 分子量: 392.5
• InChiKey: DESCCMSFWJYIPJ-QWKHPXNBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  26
• 可旋转键数：
  18
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  76
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISEASES<br/>[FR] COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE MALADIES MÉTABOLIQUES
  申请人：KANDULA MAHESH

  公开号：WO2015028927A1

  公开（公告）日：2015-03-05

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of metabolic diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of depression, liver disease, and the pain of osteoarthritis, cancer, Parkinson's disease, cancer, cardiovascular diseases, diabetes, hyperglycemia and other metabolic diseases which involve deficiency of SAM.

  该发明涉及公式I的化合物或其药用可接受的盐，以及其多晶型、溶剂合物、对映体、立体异构体和水合物。包括公式I化合物的有效量的药物组合物，以及用于治疗代谢疾病的方法可以制成口服、颊下、直肠、局部、经皮、经粘膜、静脉、肠道、糖浆或注射剂形式。这些组合物可以用于治疗抑郁症、肝病、骨关节炎疼痛、癌症、帕金森病、癌症、心血管疾病、糖尿病、高血糖和其他涉及SAM缺乏的代谢性疾病。
• [EN] FATTY ACID CONJUGATES AND THEIR USES<br/>[FR] CONJUGUÉS D'ACIDES GRAS ET LEURS UTILISATIONS
  申请人：KANDULA MAHESH

  公开号：WO2014106805A2

  公开（公告）日：2014-07-10

  The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing metabolic syndrome, cancer, a metabolic disease, a neurodegenerative disease and insulin resistance and diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of diabetes mellitus, obesity, lipid disorders, neuropathic pain, hypertriglyceridemia, hyperglycemia, hyperinsulinemia, metabolic syndrome, cancer, metabolic disease, neurodegenerative diseases and insulin resistance.
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DES TROUBLES NEUROMUSCULAIRES
  申请人：KANDULA MAHESH

  公开号：WO2014191885A2

  公开（公告）日：2014-12-04

  The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II, and methods for the treatment of neuromuscular disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of arthritis, congestive heart failure, Parkinson's disease, disuse atrophy, gyrate atrophy, McArdle's disease, Huntington's disease, mitochondrial diseases, muscular dystrophy, neuroprotection and depression.